RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
-4.26%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$1.49B
AUM Growth
+$1.49B
(-6.3%)
Cap. Flow
+$12.7M
Cap. Flow
% of AUM
0.85%
Top 10 Holdings %
Top 10 Hldgs %
30.22%
Holding
143
New
5
Increased
55
Reduced
19
Closed
10
Top Buys
| 1 |
UnitedHealth
UNH
|
$26.4M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$24.2M |
| 3 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$12.5M |
| 4 |
Bristol-Myers Squibb
BMY
|
$11.7M |
| 5 |
Merck
MRK
|
$9.57M |
Top Sells
| 1 |
Pfizer
PFE
|
$35.8M |
| 2 |
HCA Healthcare
HCA
|
$32.5M |
| 3 |
McKesson
MCK
|
$13.7M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$6.83M |
| 5 |
GI
EndoChoice Holdings, Inc.
GI
|
$5.77M |
Sector Composition
| 1 | Healthcare | 81.35% |
| 2 | Financials | 4.56% |
| 3 | Industrials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HRC
101
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $2.67M | 0.18% |
47,500
-72,500
| -60% | -$4.07M |
|
102
Exelixis
EXEL
$9.95B
| $2.61M | 0.17% |
175,000
+50,000
| +40% | +$745K |
|
103
Madrigal Pharmaceuticals
MDGL
$9.7B
| $2.61M | 0.17% |
174,891
+111,891
| +178% | +$1.67M |
|
|
DBVT
104
DBV Technologies
DBVT
$249M
| $2.56M | 0.17% |
7,300
| – | – |
|
105
SCYNEXIS
SCYX
$35.2M
| $2.42M | 0.16% |
76,000
+12,500
| +20% | +$399K |
|
106
Rigel Pharmaceuticals
RIGL
$710M
| $2.38M | 0.16% |
100,000
-81,000
| -45% | -$1.93M |
|
|
EGLT
107
DELISTED
Egalet Corporation
EGLT
| $2.3M | 0.15% |
300,000
| – | – |
|
108
Spyre Therapeutics
SYRE
$1.02B
| $2.28M | 0.15% |
20,964
| – | – |
|
109
Seres Therapeutics
MCRB
$162M
| $2.18M | 0.15% |
11,000
| – | – |
|
110
Zimmer Biomet
ZBH
$20.8B
| $2.18M | 0.15% |
+21,733
| New | +$2.18M |
|
111
HealthEquity
HQY
$8.26B
| $2.03M | 0.14% |
+50,000
| New | +$2.03M |
|
|
GNCA
112
DELISTED
Genocea Biosciences, Inc.
GNCA
| $1.98M | 0.13% |
60,000
| – | – |
|
|
BLUE
113
DELISTED
bluebird bio
BLUE
| $1.76M | 0.12% |
2,200
+656
| +42% | +$524K |
|
114
NovoCure
NVCR
$1.35B
| $1.68M | 0.11% |
214,316
| – | – |
|
|
GBT
115
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.39M | 0.09% |
96,500
-1,500
| -2% | -$21.7K |
|
116
Tandem Diabetes Care
TNDM
$834M
| $1.28M | 0.09% |
59,500
| – | – |
|
|
DMTX
117
DELISTED
Dimension Therapeutics, Inc
DMTX
| $1.18M | 0.08% |
271,370
| – | – |
|
|
MYOV
118
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.12M | 0.07% |
+89,600
| New | +$1.12M |
|
|
ALPN
119
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $1.1M | 0.07% |
122,250
| – | – |
|
120
Bausch Health
BHC
$2.72B
| $1.04M | 0.07% |
71,400
+2,800
| +4% | +$40.7K |
|
121
Novavax
NVAX
$1.2B
| $1.03M | 0.07% |
41,000
-1,625
| -4% | -$40.9K |
|
|
ATYR
122
aTyr Pharma
ATYR
$560M
| $1.02M | 0.07% |
33,929
+2,965
| +10% | +$89.2K |
|
|
CHMA
123
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $960K | 0.06% |
492,500
| – | – |
|
124
Perrigo
PRGO
$3.21B
| $774K | 0.05% |
9,300
-28,600
| -75% | -$2.38M |
|
125
Dynavax Technologies
DVAX
$1.19B
| $652K | 0.04% |
165,000
| – | – |
|